These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4576115)

  • 41. [Rifomycin in continuous and intermittent combined treatment of experimental tuberculosis in mice].
    Grumbach F
    Acta Tuberc Pneumol Belg; 1969; 60(3):390-6. PubMed ID: 5371670
    [No Abstract]   [Full Text] [Related]  

  • 42. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
    Baldan HM; De Rosa HJ; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Nov; 28(8):409-13. PubMed ID: 17828712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Rifampicine in tuberculosis. Peculiarity of its experimental activity and new therapeutic prospects].
    Le Lirzin M; Grumbach F
    Pathol Biol (Paris); 1972 Oct; 20(19):785-92. PubMed ID: 4628424
    [No Abstract]   [Full Text] [Related]  

  • 44. Isoniazid prophylaxis in experimental tuberculosis. Comparison of single versus multiple daily doses.
    Bjerkedal T; Palmer CE
    Scand J Respir Dis; 1966; 47(2):131-49. PubMed ID: 4957691
    [No Abstract]   [Full Text] [Related]  

  • 45. [Risk of acquisition of RFP resistance out of INH resistant RFP susceptible tuberculosis].
    Yoshiyama T; Ito K; Ogata H; Aono A; Wada M
    Kekkaku; 2005 Jan; 80(1):9-14. PubMed ID: 15839057
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of hypoglycemic drugs on results of treatment with nicotinic acid hydrazide in experimental tuberculosis in guinea pigs, caused by Mycobacterium tuberculosis of low resistance to INH].
    Kulig A
    Patol Pol; 1968; 19(1):237-41. PubMed ID: 4968014
    [No Abstract]   [Full Text] [Related]  

  • 47. [Antibacterian activity modifications of serum isoniazid when using it with rifampicin (author's transl)].
    Nouhouayi A; Bergogne-Berezin E; Lafaix C
    Pathol Biol (Paris); 1982 Jun; 30(6):389-93. PubMed ID: 7050848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Experimental studies on the effects of INH treatment on the morphologic dynamics of tuberculosis in animals vaccinated with BCG].
    Eskenasy A
    Z Tuberk Erkr Thoraxorg; 1965; 124(5):316-23. PubMed ID: 5899164
    [No Abstract]   [Full Text] [Related]  

  • 49. [Effect of rifampicin on the nonspecific reactivity and natural resistence to tuberculosis in guinea pigs].
    Shiniberov VA
    Probl Tuberk; 1979 Jan; (1):50-4. PubMed ID: 419108
    [No Abstract]   [Full Text] [Related]  

  • 50. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [An experimental study on the antituberculous activity of rifampicin].
    Toyoara M
    Kekkaku; 1971 Jun; 46(6):211-6. PubMed ID: 4997827
    [No Abstract]   [Full Text] [Related]  

  • 52. [Intermittent ethambutol therapy of experimental tuberculosis in guinea pigs].
    Lucchesi M; Mancini P; Matzeu M
    Ann Ist Carlo Forlanini; 1968; 28(4):369-79. PubMed ID: 5738473
    [No Abstract]   [Full Text] [Related]  

  • 53. [The effect of a combination of INH, Rifadin and Miambutol in generalized tuberculosis].
    Djurisić M; Jovanović M; Vlahović M
    Glas Srp Akad Nauka Med; 1981; (33):153-8. PubMed ID: 6927233
    [No Abstract]   [Full Text] [Related]  

  • 54. Laboratory aspects of intermittent drug therapy.
    Mitchison DA; Dickinson JM
    Postgrad Med J; 1971 Nov; 47(553):737-41. PubMed ID: 4110538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Levamisole treatment of experimental tuberculosis].
    Aleksandrova AE; Zabolotnykh NV
    Probl Tuberk; 1981 Oct; (10):55-8. PubMed ID: 7312854
    [No Abstract]   [Full Text] [Related]  

  • 57. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
    Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
    J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of ketoconazole with rifampin and isoniazid.
    Engelhard D; Stutman HR; Marks MI
    N Engl J Med; 1984 Dec; 311(26):1681-3. PubMed ID: 6095080
    [No Abstract]   [Full Text] [Related]  

  • 59. Rapid direct detection of multiple rifampin and isoniazid resistance mutations in Mycobacterium tuberculosis in respiratory samples by real-time PCR.
    Marín M; García de Viedma D; Ruíz-Serrano MJ; Bouza E
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4293-300. PubMed ID: 15504855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.
    LoBue PA; Moser KS
    Int J Tuberc Lung Dis; 2005 May; 9(5):501-6. PubMed ID: 15875920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.